Published in Blood on December 19, 2002
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood (2006) 3.88
X-linked clonality testing: interpretation and limitations. Blood (2007) 2.04
Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol (2007) 1.98
Hematopoiesis is not clonal in healthy elderly women. Blood (2008) 1.95
Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance. Circ Res (2006) 1.95
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood (2013) 1.33
In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele. Exp Hematol (2007) 1.26
Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol (2010) 1.12
CD177: A member of the Ly-6 gene superfamily involved with neutrophil proliferation and polycythemia vera. J Transl Med (2004) 1.00
Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia (2015) 0.95
Methylation of AR locus does not always reflect X chromosome inactivation state. Blood (2012) 0.93
Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera. Clin Immunol (2006) 0.87
An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions. J Immunol (2006) 0.87
Recent advances in the bcr-abl negative chronic myeloproliferative diseases. J Transl Med (2006) 0.80
Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2(V617F) allelic burden. Exp Hematol Oncol (2016) 0.75
A novel unconventional antigen MPD5 elicits anti-tumor humoral immune responses in a subset of patients with polycythemia vera. Int J Immunopathol Pharmacol (2007) 0.75
Back to biology: new insights on inheritance in myeloproliferative disorders. Curr Hematol Malig Rep (2014) 0.75
Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood (2006) 8.56
Essential role for Nix in autophagic maturation of erythroid cells. Nature (2008) 6.49
Genetic evidence for high-altitude adaptation in Tibet. Science (2010) 5.37
Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet (2011) 4.85
Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet (2002) 4.06
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood (2005) 3.24
LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One (2007) 2.99
Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol (2002) 2.77
Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol (2007) 2.75
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med (2012) 2.74
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol (2007) 2.40
Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development. J Biol Chem (2006) 2.39
Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood (2004) 2.27
DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol (2009) 2.23
Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med (2006) 2.23
Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood (2004) 2.12
X-linked clonality testing: interpretation and limitations. Blood (2007) 2.04
Endothelin-1, vascular endothelial growth factor and systolic pulmonary artery pressure in patients with Chuvash polycythemia. Haematologica (2006) 2.04
Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res (2007) 2.02
Congenital polycythemias/erythrocytoses. Haematologica (2005) 1.99
Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol (2007) 1.98
Hematopoiesis is not clonal in healthy elderly women. Blood (2008) 1.95
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol (2005) 1.93
Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood (2008) 1.71
Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res (2007) 1.68
Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood (2002) 1.65
Genetic association analysis of chronic mountain sickness in an Andean high-altitude population. Haematologica (2005) 1.59
Quantification of fibrosis and osteosclerosis in myeloproliferative neoplasms: a computer-assisted image study. Leuk Res (2010) 1.54
Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer. Genome Res (2010) 1.53
Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood (2003) 1.52
Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood (2008) 1.52
Copper deficiency masquerading as myelodysplastic syndrome. Blood (2002) 1.51
Detection of JAK2 mutations in paraffin marrow biopsies by high resolution melting analysis: identification of L611S alone and in cis with V617F in polycythemia vera. Leuk Lymphoma (2012) 1.46
Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Res (2006) 1.46
Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One (2008) 1.46
Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res (2010) 1.38
Aberrant expression of microRNA in polycythemia vera. Haematologica (2008) 1.37
The evolution of cellular deficiency in GATA2 mutation. Blood (2013) 1.36
DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res (2012) 1.35
Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood (2005) 1.35
CpG island methylation profiling in human melanoma cell lines. Melanoma Res (2009) 1.35
Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica (2008) 1.33
Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res (2007) 1.33
Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation. J Biol Chem (2007) 1.32
New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol (2013) 1.32
Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res (2014) 1.30
Vascular complications in Chuvash polycythemia. Semin Thromb Hemost (2006) 1.29
Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics (2012) 1.29
Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol Dis (2002) 1.28
In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele. Exp Hematol (2007) 1.26
Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res (2006) 1.26
Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res (2009) 1.24
Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res (2006) 1.24
Disruption of ferroportin 1 regulation causes dynamic alterations in iron homeostasis and erythropoiesis in polycythaemia mice. Development (2004) 1.21
Genetic determinants of Tibetan high-altitude adaptation. Hum Genet (2011) 1.21
Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. Cancer Res (2010) 1.20
Lessons from familial myeloproliferative disorders. Semin Hematol (2005) 1.20
Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prev (2011) 1.19
Frequent alteration of MLL3 frameshift mutations in microsatellite deficient colorectal cancer. PLoS One (2011) 1.19
Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence. Biochim Biophys Acta (2006) 1.16
Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia. Haematologica (2010) 1.16
Dysregulation of ferroportin 1 interferes with spleen organogenesis in polycythaemia mice. Development (2004) 1.14
Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood (2007) 1.13
A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl) (2012) 1.13
Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One (2011) 1.12
Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. Am J Hum Genet (2003) 1.10
Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. Gastroenterology (2009) 1.10
Age-related epigenetic drift in the pathogenesis of MDS and AML. Genome Res (2014) 1.08
Concordant DNA methylation in synchronous colorectal carcinomas. Cancer Prev Res (Phila) (2009) 1.08
Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Blood (2013) 1.07
Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease. PLoS One (2009) 1.07
Divalent metal transporter 1. Hematology (2005) 1.07
The worldwide distribution of the VHL 598C>T mutation indicates a single founding event. Blood (2003) 1.07
Hypoxia. 5. Hypoxia and hematopoiesis. Am J Physiol Cell Physiol (2011) 1.07
Delta DNMT3B variants regulate DNA methylation in a promoter-specific manner. Cancer Res (2007) 1.06
miR-451 enhances erythroid differentiation in K562 cells. Leuk Lymphoma (2010) 1.06
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol (2013) 1.05
Sickle cell disease resulting from uniparental disomy in a child who inherited sickle cell trait. Blood (2010) 1.04
Treatment target in polycythemia vera. N Engl J Med (2013) 1.02
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma (2007) 1.02
Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica (2006) 0.98
The phenotype of polycythemia due to Croatian homozygous VHL (571C>G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C>T:R200W). Haematologica (2013) 0.97